Health and Healthcare

Amgen : AMGN

All Amgen Articles

701 Articles

Chris Lange | Nov 28, 2018 at 8:20 AM EST

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The November 15 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | Nov 12, 2018 at 8:50 AM EST

Short Sellers Raise the Stakes in Major Biotechs

The October 31 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 25, 2018 at 8:20 AM EDT

Short Sellers Hike Their Bets in Major Biotechs

The October 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 10, 2018 at 8:20 AM EDT

Short Sellers Back Off Major Biotechs

The September 28 short interest data have been compared with the previous report, and short interest in most of the…

Lee Jackson | Oct 1, 2018 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Amgen, Chipotle, Lam Research, Netgear, Teva Pharmaceutical, Western Digital and More

The top analyst upgrades, downgrades and initiations seen on Monday included Amgen, Chipotle Mexican Grill, Lam Research, Netgear, Teva Pharmaceutical…

Lee Jackson | Sep 27, 2018 at 8:35 AM EDT

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term,…

Chris Lange | Sep 26, 2018 at 8:15 AM EDT

Major Biotechs Have Short Sellers on the Run

The September 14 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Sep 13, 2018 at 8:20 AM EDT

Short Sellers Up the Ante in Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data…

Chris Lange | Aug 27, 2018 at 7:05 AM EDT

Short Sellers Run for Cover From Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | Aug 15, 2018 at 11:50 AM EDT

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors.…

Chris Lange | Aug 10, 2018 at 8:45 AM EDT

Why Have Short Sellers Backed Off Major Biotechs?

The July 31 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | Jul 30, 2018 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Ally, Amgen, AT&T, BP, Chesapeake Energy, Expedia, NOV, Square, Synchrony, Twitter and More

The top analyst upgrades, downgrades and other research calls from Monday includes Ally Financial, Amgen, AT&T, BP, Chesapeake Energy, Expedia,…

Chris Lange | Jul 25, 2018 at 7:10 AM EDT

Major Biotechs See a Rising Tide of Short Interest

The July 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jul 22, 2018 at 10:25 AM EDT

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

24/7 Wall St. has put together a preview of AbbVie, Eli Lilly, Gilead Sciences and some of the other, larger…

Chris Lange | Jul 12, 2018 at 8:21 AM EDT

Short Sellers Back Off Major Biotechs

The June 29 short interest data have been compared with the previous report, and short interest in most of the…

1 … 14 15 16 17 18 … 47

Amgen : AMGN

All Amgen Articles

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Short Sellers Raise the Stakes in Major Biotechs

Short Sellers Hike Their Bets in Major Biotechs

Short Sellers Back Off Major Biotechs

Top Analyst Upgrades and Downgrades: Amgen, Chipotle, Lam Research, Netgear, Teva Pharmaceutical, Western Digital and More

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

Major Biotechs Have Short Sellers on the Run

Short Sellers Up the Ante in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

Why Have Short Sellers Backed Off Major Biotechs?

Top Analyst Upgrades and Downgrades: Ally, Amgen, AT&T, BP, Chesapeake Energy, Expedia, NOV, Square, Synchrony, Twitter and More

Major Biotechs See a Rising Tide of Short Interest

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

Short Sellers Back Off Major Biotechs

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Amgen : AMGN

All Amgen Articles

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Short Sellers Raise the Stakes in Major Biotechs

Short Sellers Hike Their Bets in Major Biotechs

Short Sellers Back Off Major Biotechs

Top Analyst Upgrades and Downgrades: Amgen, Chipotle, Lam Research, Netgear, Teva Pharmaceutical, Western Digital and More

Merrill Lynch Loves Large Cap Biotech: 4 Top Stocks to Buy Now

Major Biotechs Have Short Sellers on the Run

Short Sellers Up the Ante in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

Why Have Short Sellers Backed Off Major Biotechs?

Top Analyst Upgrades and Downgrades: Ally, Amgen, AT&T, BP, Chesapeake Energy, Expedia, NOV, Square, Synchrony, Twitter and More

Major Biotechs See a Rising Tide of Short Interest

Amgen, Eli Lilly, Gilead and More Major Health Care Companies Reporting This Week

Short Sellers Back Off Major Biotechs

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

Featured Reads

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase